Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,400,075 papers from all fields of science
Search
Sign In
Create Free Account
refractory cancer
Known as:
clinical resistance
, resistant cancer
, cancer refractory
Expand
Cancer that does not respond to treatment. The cancer may be resistant at the beginning of treatment, or it may become resistant during treatment.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Neoplastic Cell
cancer cell
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Accepted Manuscript Title : Long Non-coding RNAs : an Emerging Powerhouse in the Battle between Life and Death of Tumor Cells
X. Xiong
,
X. Ren
,
Meng-yun Cai
,
Jay W. Yang
,
Xinguang Liu
,
Jin-Ming Yang
2016
Corpus ID: 3294818
Highly Cited
2009
Highly Cited
2009
Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer
E. Briasoulis
,
P. Pappas
,
+5 authors
N. Pavlidis
Clinical Cancer Research
2009
Corpus ID: 9578142
Aim: To determine the safe dose range and pharmacokinetics of metronomic oral vinorelbine and obtain preliminary data on…
Expand
Review
2006
Review
2006
Anti-galectin compounds as potential anti-cancer drugs.
L. Ingrassia
,
I. Camby
,
+4 authors
R. Kiss
Current Medicinal Chemistry
2006
Corpus ID: 34972476
Galectins form a family of carbohydrate-binding proteins defined by their affinity for beta-galactosides containing…
Expand
Highly Cited
2004
Highly Cited
2004
Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines.
Frantisek Zák
,
J. Turánek
,
+10 authors
A. Kozubík
Journal of Medicinal Chemistry
2004
Corpus ID: 38536799
Procedure of the synthesis is described for new platinum(IV) drug LA-12 [(OC-6-43)-bis(acetato)(1-adamantylamine…
Expand
Review
2003
Review
2003
Targeting cancer cells by exploiting their resistance.
M. Blagosklonny
Trends in Molecular Medicine
2003
Corpus ID: 31888588
Highly Cited
2001
Highly Cited
2001
Inhibitory effect of steroidal alkaloids on drug transport and multidrug resistance in human cancer cells.
Y. Lavie
,
T. Harel-Orbital
,
William Gaffield
,
M. Liscovitch
Anticancer Research
2001
Corpus ID: 10636337
Intrinsic or acquired resistance of tumor cells to multiple cytotoxic drugs (multidrug resistance MDR) is a major cause of…
Expand
Review
2001
Review
2001
Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents.
G. Krystal
Drug resistance updates
2001
Corpus ID: 23081921
Imatinib (STI571, Glivec) is a small molecule drug selected for its ability to inhibit the Bcr-Abl kinase, the pathogenic…
Expand
Highly Cited
1986
Highly Cited
1986
Administration of intraspinal morphine sulfate for the treatment of intractable cancer pain.
A. Shetter
,
M. Hadley
,
E. Wilkinson
1986
Corpus ID: 53757490
A total of 24 patients with intractable cancer pain were evaluated as candidates for spinal morphine therapy. Temporary trials…
Expand
Highly Cited
1984
Highly Cited
1984
Improved control of bulky prostate carcinoma with sequential estrogen and radiation therapy.
N. Green
,
H. Bodner
,
+7 authors
J. Jaffe
International Journal of Radiation Oncology…
1984
Corpus ID: 24623295
Highly Cited
1981
Highly Cited
1981
High-dose combined-modality therapy and autologous bone marrow transplantation in resistant cancer.
D. Douer
,
R. Champlin
,
+5 authors
R. Gale
American Journal of Medicine
1981
Corpus ID: 9146672
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE